Justicia carnea extract alleviates oxidative stress in pancreatitis
Background and objectives Chronic pancreatitis is an inflammatory disease and is difficult to manage despite advancements in medical…
Scientists rethink GLP-1 delivery to improve dosing, tolerability, and adherence
From microneedles to nanocarriers, researchers are rethinking how GLP-1 medicines could become longer-lasting, easier to tolerate, and more…
Popular GLP-1 drugs significantly reduce major cardiovascular events,
Widely used diabetes and obesity drugs show powerful heart-protective effects in high-risk patients, offering new momentum for their…
A new tool that predicts obesity-related disease risk beyond BMI
A data-driven tool built from nearly 200,000 individuals reveals who is most likely to develop serious obesity-related diseases,…
People judge weight loss more harshly when GLP-1 drugs are involved, study finds
Even when medication is paired with diet and exercise, people may still feel their weight loss is less…
Endoscopic procedure may prevent weight regain after GLP-1 discontinuation
An outpatient procedure may offer a way for the estimated 70% of people who discontinue popular weight-loss drugs…
Study finds GLP-1 medicines cut fat while preserving muscle function
A new study in mice and humans suggests GLP-1 medicines drive weight loss primarily by reducing fat, while…
Patients who stop GLP-1 drugs often restart or try alternatives
A large real-world study shows that patients who stop popular GLP-1–based weight-loss drugs often return to treatment or…
Could GLP-1 drugs help curb addiction? Large veteran study points to potential benefit
A major study of US veterans suggests that GLP-1 diabetes medications may influence addiction-related outcomes, revealing a surprising…
Engineered lettuce may turn injectable GLP-1 therapies into oral pills
Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists.…
Mapping the year-one weight trajectory after stopping GLP-1s
A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain, on average, 60%…
How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?
A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for obesity and diabetes, delivering powerful…